Celldex Therapeutics
CLDX
174 hedge funds and large institutions have $1.86B invested in Celldex Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 48 reducing their positions, and 36 closing their positions.
46% more call options, than puts
Call options by funds: $24.9M | Put options by funds: $17.1M
38% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 48
2.75% more ownership
Funds ownership: 108.33% → 111.07% (+2.7%)
6% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 36
1% less funds holding
Funds holding: 176 → 174 (-2)
24% less capital invested
Capital invested by funds: $2.44B → $1.86B (-$579M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| 1 |
JFG
Jefferies Financial Group
New York
|
+$64.4M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$43.6M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$41.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.7M |
| 5 |
Morgan Stanley
New York
|
+$24.7M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAP
201
Arax Advisory Partners
Denver,
Colorado
| – | -$4.72K | -139 | Closed |
|
|
QT
202
Quantbot Technologies
New York
| – | -$3.23K | -95 | Closed |
|
|
VCM
203
Versant Capital Management
Phoenix,
Arizona
| – | -$3.13K | -92 | Closed |
|
|
CFD
204
Creative Financial Designs
Kokomo,
Indiana
| – | -$2.82K | -83 | Closed |
|
205
Bessemer Group
Woodbridge,
New Jersey
| – | -$2K | -60 | Closed |
|
|
BTI
206
Blue Trust Inc
Alpharetta,
Georgia
| – | -$2.18K | -59 | Closed |
|
|
UB
207
UMB Bank
Kansas City,
Missouri
| – | -$68 | -2 | Closed |
|
208
AssetMark Inc
Concord,
California
| – | -$34 | -1 | Closed |
|
|
C
209
Covestor
London,
United Kingdom
| – | +$82 | +3 | +100% |
|
CLDX Hedge Fund Activity: Q4 2024 in Review
174 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2024, worth a combined $1.86B — down 24% from $2.44B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of CLDX and 34 opened new positions — a net loss of 2 holders — while 48 trimmed existing stakes and 66 added.
The largest buyer was Jefferies Financial Group, adding an estimated $64.4M. The largest seller was Commodore Capital, exiting entirely with an estimated $55M sold.
- 174 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2024, down from 176 in Q3 2024.
- Funds reported $1.86B of Celldex Therapeutics stock for Q4 2024, down 24% quarter-over-quarter.
- 34 funds opened new Celldex Therapeutics positions in Q4 2024 and 36 closed out, a net change of -2 holders.
- The largest Celldex Therapeutics buyer in Q4 2024 was Jefferies Financial Group, an estimated $64.4M added.
- The largest Celldex Therapeutics seller in Q4 2024 was Commodore Capital, an estimated $55M sold.
Based on aggregated 13F filings for Q4 2024.